Sarcoidosis Epidemiology Summary

• Sarcoidosis is a multisystem inflammatory disease characterized by non-necrotizing granuloma formation in various organs and thought to result from a complex interaction between genetic predisposition and environmental triggers.
• Elderly-onset sarcoidosis (EOS) is a less frequent variant of sarcoidosis with limited data regarding the possible risk factors.
• Since sarcoidosis is rare and symptoms vary widely, people can go for years without knowing they have it.
• It is a multisystem granulomatous disease affecting 8–10 per 100,000 individuals (United States), with pulmonary (90%), cardiac (5–25%), renal (10%), hepatic (20%), and neurologic (5–10%) involvement.
• Despite ongoing therapeutic advancements, chronic disease progression, organ damage, and the absence of validated biomarkers remain significant clinical challenges.

Sarcoidosis Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalence of Sarcoidosis: ~XXXX
• 2036 Diagnosed Prevalence of Sarcoidosis: ~XXXX
• Sarcoidosis Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's ‘Sarcoidosis Epidemiology Forecast 2036’ report delivers an in-depth understanding of the sarcoidosis, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Sarcoidosis Understanding and Diagnosis Algorithm

Sarcoidosis Overview

Sarcoidosis is a rare, multisystem inflammatory disease characterized by the formation of non-caseating granulomas in affected organs. Although the exact cause remains unknown, the disease is believed to result from an abnormal immune response triggered by environmental, infectious, or genetic factors in susceptible individuals. Sarcoidosis can affect virtually any organ, but the lungs and intrathoracic lymph nodes are involved in more than 90% of cases. Other commonly affected organs include the skin, eyes, liver, heart, and nervous system. The clinical presentation is highly variable, ranging from asymptomatic disease to chronic progressive organ dysfunction.

Further details are provided in the report.

Sarcoidosis Diagnosis

The diagnosis of sarcoidosis is based on a combination of clinical findings, radiographic evidence, histological confirmation of non-caseating granulomas, and exclusion of alternative granulomatous disorders such as tuberculosis or fungal infections. Chest X-ray and high-resolution computed tomography (HRCT) are commonly used to assess pulmonary involvement, while pulmonary function tests help evaluate respiratory impairment. Tissue biopsy obtained from accessible sites such as lymph nodes, skin lesions, or lung tissue is often required to confirm the diagnosis. Additional laboratory tests and organ-specific evaluations may be performed to determine the extent of systemic involvement and monitor disease activity.

Further details are provided in the report.

Sarcoidosis Epidemiology

Key Findings from Sarcoidosis Epidemiological Analysis and Forecast 

• According to the American Lung Association, sarcoidosis is a rare disease, with an estimated 150,000–200,000 cases in the US each year and approximately 27,000 new cases diagnosed annually.
• Sarcoidosis most commonly occurs in individuals between the ages of 20 and 60. While it was originally recognized in younger adults, current clinical observations show that over half of cases are now diagnosed in patients over 40 years old. Women, in particular, tend to be older at the time of diagnosis.
• According to secondary research data, the worldwide prevalence of sarcoidosis is about 4.7–64/100,000 people.
• Spontaneous remission occurring in 10 to 82% of cases and 10% developing advanced pulmonary sarcoidosis.

Scope of the Report

• The report covers a segment of a descriptive overview of sarcoidosis, explaining their causes, signs and symptoms, and pathogenesis.

• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Sarcoidosis Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of sarcoidosis? What will be the growth opportunities across the 7MM concerning the patient population with sarcoidosis?
• What is the historical and forecasted sarcoidosis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.